PKC Activator Selection for Ras-Mutant Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PKC inhibitors have shown inconsistent therapeutic effects in cancer treatment due to the differential roles of PKC isoforms in tumor formation and progression, with some activating PKC compounds promoting tumors rather than inhibiting them, and the uncertainty in selecting cancer types sensitive to PKC activators.
Innovation Solution
A method to select cancers sensitive to PKC activators by determining PKC activation potential and oncogenic K-ras and/or N-ras activity, using diterpenoid PKC activators for targeted cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PKC inhibitors are used to treat cancer, then PKC activity is reduced, but therapeutic effect is inconsistent and unreliable
Solution Approach 1:
The patent changes the therapeutic approach from PKC inhibition to PKC activation, and further refines it by selecting specific PKC isoforms (δ and μ) for activation. This parameter change in the mechanism of action and target specificity resolves the inconsistency in therapeutic effects by targeting the specific isoforms that drive tumor progression rather than all PKC isoforms uniformly.
Solution Approach 2:
The patent segments the PKC family into specific isoforms (δ and μ) that are responsible for tumor progression, rather than treating all PKC isoforms as a single target. This segmentation allows for selective activation of only the pathogenic isoforms while sparing protective isoforms, thereby improving reliability and reducing off-target effects.
2Reliability
If PKC activators are used to treat cancer, then some cancer cells are inhibited, but some cancer types show tumor promotion instead of inhibition
Solution Approach 1:
The patent changes the activation approach from non-selective PKC activation to selective activation of specific isoforms (δ and μ) using compounds like prostratin and ingenol-3-angelate. This selective parameter change ensures activation of only the isoforms involved in tumor progression, preventing the tumor-promoting effects observed with non-selective activators.
Solution Approach 2:
The patent applies local quality by targeting specific PKC isoforms (δ and μ) with distinct pharmacological properties rather than activating all PKC isoforms uniformly. This allows different regions of the PKC system to have different functional outcomes, activating only the pathogenic isoforms while leaving protective isoforms unaffected.
3Adaptability or versatility
If non-selective PKC activation is used, then broad cancer cell coverage is achieved, but specificity for sensitive cancer types is lost
Solution Approach 1:
The patent changes the selection criterion from broad PKC activation response to specific biomarker presence (oncogenic K-ras and/or N-ras mutations). This parameter change in the selection methodology provides precise prediction of which cancer types will respond to PKC activator treatment, improving both specificity and adaptability.
Solution Approach 2:
The patent implements feedback by using the presence of oncogenic K-ras and/or N-ras mutations as a predictive biomarker to guide treatment selection. This feedback mechanism ensures that PKC activators are administered only to patients whose cancer types are likely to respond, thereby improving measurement precision of cancer sensitivity while maintaining adaptability to different cancer types with these mutations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Identifies cancer types responsive to PKC activators, enhancing therapeutic efficacy by inhibiting cancer cell proliferation effectively.
Implementation Method 1
The level of PKC activation can be determined by any method known in the art, for example, by detecting the level of phosphorylation of a PKC substrate or by detecting the level of activation of a PKC enzyme.
Data Source
AI summary
This present disclosure is directed to a method of selecting a cancer for treatment with protein kinase C (PKC) activators, and corresponding methods of treating the cancer with PKC activators.